MicroRNA‑876‑5p inhibits the progression of glioblastoma multiforme by directly targeting Forkhead box M1 Retraction in /10.3892/or.2022.8360

Wang,Lina; Lu,Jia; Zhang,Hong; Lyu,Xueman; Sun,Zhigang

doi:10.3892/or.2018.6804

MicroRNA‑876‑5p inhibits the progression of glioblastoma multiforme by directly targeting Forkhead box M1

Retraction in: /10.3892/or.2022.8360

Authors:
- Lina Wang
- Jia Lu
- Hong Zhang
- Xueman Lyu
- Zhigang Sun
View Affiliations

Affiliations: Department of Ophthalmology, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Neurosurgery, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China
Published online on: October 17, 2018 https://doi.org/10.3892/or.2018.6804
Pages: 702-710

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Considerable evidence has suggested that microRNAs (miRNAs) are dysregulated in glioblastoma multiforme (GBM), and their dysregulation may modulate the aggressiveness of GBM. Therefore, miRNAs with dysregulated expression are potential therapeutic targets for the treatment of GBM. miRNA‑876‑5p (miR‑876‑5p) has recently been identified to be aberrantly expressed and serve an important role in hepatocellular carcinoma and lung cancer. However, its expression pattern and functional significance in GBM remains largely unknown. Therefore, the present study detected miR‑876‑5p expression in GBM, examined the biological roles of miR‑876‑5p in GBM progression and explored its underlying mechanism. The present study demonstrated that miR‑876‑5p expression was significantly downregulated in GBM tissues and cell lines. Overexpression of miR‑876‑5p restricted the proliferation, induced the apoptosis and reduced the migration and invasion capabilities of GBM cells. In GBM cells, Forkhead box M1 (FOXM1) was identified as a direct target of miR‑876‑5p. FOXM1 was overexpressed in clinical GBM tissues, and its overexpression was inversely correlated with miR‑876‑5p level. Small interfering RNA‑mediated knockdown of FOXM1 exhibited effects similar to those of miR‑876‑5p overexpression in GBM cells. The tumour suppressive roles of miR‑876‑5p overexpression in GBM cells were significantly reversed by FOXM1 reintroduction. Overall, the present results revealed that miR‑876‑5p may inhibit the development of GBM by directly targeting FOXM1, suggesting that this miRNA may be a potential therapeutic target in patients, for the management of GBM.

View Figures

View References

1	Caldarella A and Barchielli A: Glioblastoma in the canton of Zurich, Switzerland revisited: 2005 to 2009. Cancer. 122:37402016. View Article : Google Scholar : PubMed/NCBI
2	Komori T, Sasaki H and Yoshida K: Revised WHO classification of tumours of the central nervous system: Summary of the revision and perspective. No Shinkei Geka. 44:625–635. 2016.(In Japanese). PubMed/NCBI
3	Ohgaki H and Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 170:1445–1453. 2007. View Article : Google Scholar : PubMed/NCBI
4	Rigamonti A, Imbesi F, Silvani A, Grimod G, Prone V, Gaviani P, Ardizzoia A, Milanesi I, Arienti V, Agostoni E, et al: Pattern of care and outcome in elderly patients with glioblastoma: Data in 151 patients from 3 Lombardia Hospitals. J Neurol Sci. 378:3–8. 2017. View Article : Google Scholar : PubMed/NCBI
5	Komotar RJ, Otten ML, Moise G and Connolly ES Jr: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma-A critical review. Clin Med Oncol. 2:421–422. 2008.PubMed/NCBI
6	Khosla D: Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma. Ann Transl Med. 4:542016.PubMed/NCBI
7	Marumoto T and Saya H: Molecular biology of glioma. Adv Exp Med Biol. 746:2–11. 2012. View Article : Google Scholar : PubMed/NCBI
8	Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A and Enright AJ: miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 34:D140–D144. 2006. View Article : Google Scholar : PubMed/NCBI
9	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
10	Chen K and Rajewsky N: The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 8:93–103. 2007. View Article : Google Scholar : PubMed/NCBI
11	Piwecka M, Rolle K, Belter A, Barciszewska AM, Żywicki M, Michalak M, Nowak S, Naskręt-Barciszewska MZ and Barciszewski J: Comprehensive analysis of microRNA expression profile in malignant glioma tissues. Mol Oncol. 9:1324–1340. 2015. View Article : Google Scholar : PubMed/NCBI
12	Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
13	Manikandan J, Aarthi JJ, Kumar SD and Pushparaj PN: Oncomirs: The potential role of non-coding microRNAs in understanding cancer. Bioinformation. 2:330–334. 2008. View Article : Google Scholar : PubMed/NCBI
14	Gu JJ, Fan KC, Zhang JH, Chen HJ and Wang SS: Suppression of microRNA-130b inhibits glioma cell proliferation and invasion, and induces apoptosis by PTEN/AKT signaling. Int J Mol Med. 41:284–292. 2018.PubMed/NCBI
15	Gomez Zubieta DM, Hamood MA, Beydoun R, Pall AE and Kondapalli KC: MicroRNA-135a regulates NHE9 to inhibit proliferation and migration of glioblastoma cells. Cell Commun Signal. 15:552017. View Article : Google Scholar : PubMed/NCBI
16	Cheng ZX, Song YX, Wang ZY, Wang Y and Dong Y: miR-144-3p serves as a tumor suppressor by targeting FZD7 and predicts the prognosis of human glioblastoma. Eur Rev Med Pharmacol Sci. 21:4079–4086. 2017.PubMed/NCBI
17	Xu X, Cai N, Zhi T, Bao Z, Wang D, Liu Y, Jiang K, Fan L, Ji J and Liu N: MicroRNA-1179 inhibits glioblastoma cell proliferation and cell cycle progression via directly targeting E2F transcription factor 5. Am J Cancer Res. 7:1680–1692. 2017.PubMed/NCBI
18	Sun J, Zheng G, Gu Z and Guo Z: MiR-137 inhibits proliferation and angiogenesis of human glioblastoma cells by targeting EZH2. J Neurooncol. 122:481–489. 2015. View Article : Google Scholar : PubMed/NCBI
19	Xu Q, Zhu Q, Zhou Z, Wang Y, Liu X, Yin G, Tong X and Tu K: MicroRNA-876-5p inhibits epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma by targeting BCL6 corepressor like 1. Biomed Pharmacother. 103:645–652. 2018. View Article : Google Scholar : PubMed/NCBI
20	Wang Y, Xie Y, Li X, Lin J, Zhang S, Li Z, Huo L and Gong R: MiR-876-5p acts as an inhibitor in hepatocellular carcinoma progression by targeting DNMT3A. Pathol Res Pract. 214:2024–2030. 2018. View Article : Google Scholar
21	Bao L, Lv L, Feng J, Chen Y, Wang X, Han S and Zhao H: MiR-876-5p suppresses epithelial-mesenchymal transition of lung cancer by directly down-regulating bone morphogenetic protein 4. J Biosci. 42:671–681. 2017. View Article : Google Scholar : PubMed/NCBI
22	Duan N, Hu X, Yang X, Cheng H and Zhang W: MicroRNA-370 directly targets FOXM1 to inhibit cell growth and metastasis in osteosarcoma cells. Int J Clin Exp Pathol. 8:10250–10260. 2015.PubMed/NCBI
23	Song BN and Chu IS: A gene expression signature of FOXM1 predicts the prognosis of hepatocellular carcinoma. Exp Mol Med. 50:e4182018. View Article : Google Scholar : PubMed/NCBI
24	Huang C, Du J and Xie K: FOX M1 and its oncogenic signaling in pancreatic cancer pathogenesis. Biochim Biophys Acta. 1845:104–116. 2014.PubMed/NCBI
25	Cao S, Lin L, Xia X and Wu H: MicroRNA-761 promotes the sensitivity of colorectal cancer cells to 5-Fluorouracil through targeting FOXM1. Oncotarget. 9:321–331. 2017.PubMed/NCBI
26	Siraj AK, Pratheeshkumar P, Parvathareddy SK, Qadri Z, Thangavel S, Ahmed S, Al-Dayel F, Tulbah A, Ajarim D and Al-Kuraya KS: FoxM1 is an independent poor prognostic marker and therapeutic target for advanced Middle Eastern breast cancer. Oncotarget. 9:17466–17482. 2018. View Article : Google Scholar : PubMed/NCBI
27	Hou Y, Li W, Sheng Y, Li L, Huang Y, Zhang Z, Zhu T, Peace D, Quigley JG, Wu W, et al: The transcription factor Foxm1 is essential for the quiescence and maintenance of hematopoietic stem cells. Nat Immunol. 16:810–818. 2015. View Article : Google Scholar : PubMed/NCBI
28	Lu XF, Zeng, Liang WQ, Chen CF, Sun SM and Lin HY: FoxM1 is a promising candidate target in the treatment of breast cancer. Oncotarget. 9:842–852. 2017.PubMed/NCBI
29	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
30	Bowman A and Nusse R: Location, location, location: FoxM1 mediates beta-catenin nuclear translocation and promotes glioma tumorigenesis. Cancer Cell. 20:415–416. 2011. View Article : Google Scholar : PubMed/NCBI
31	Zhang N, Wei P, Gong A, Chiu WT, Lee HT, Colman H, Huang H, Xue J, Liu M, Wang Y, et al: FoxM1 promotes beta-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell. 20:427–442. 2011. View Article : Google Scholar : PubMed/NCBI
32	Li Y, Zhang S and Huang S: FoxM1: A potential drug target for glioma. Future Oncol. 8:223–226. 2012. View Article : Google Scholar : PubMed/NCBI
33	Zhang N, Wu X, Yang L, Xiao F, Zhang H, Zhou A, Huang Z and Huang S: FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51. Clin Cancer Res. 18:5961–5971. 2012. View Article : Google Scholar : PubMed/NCBI
34	Wang Z, Zhang S, Siu TL and Huang S: Glioblastoma multiforme formation and EMT: Role of FoxM1 transcription factor. Curr Pharm Des. 21:1268–1271. 2015. View Article : Google Scholar : PubMed/NCBI
35	Huang SW, Ali ND, Zhong L and Shi J: MicroRNAs as biomarkers for human glioblastoma: Progress and potential. Acta Pharmacol Sin. 39:1405–1413. 2018. View Article : Google Scholar : PubMed/NCBI
36	Banelli B, Forlani A, Allemanni G, Morabito A, Pistillo MP and Romani M: MicroRNA in glioblastoma: An overview. Int J Genomics. 2017:76390842017. View Article : Google Scholar : PubMed/NCBI
37	Ahir BK, Ozer H, Engelhard HH and Lakka SS: MicroRNAs in glioblastoma pathogenesis and therapy: A comprehensive review. Crit Rev Oncol Hematol. 120:22–33. 2017. View Article : Google Scholar : PubMed/NCBI
38	Hu Q, Du K, Mao X and Ning S: miR-197 is downregulated in cervical carcinogenesis and suppresses cell proliferation and invasion through targeting forkhead box M1. Oncol Lett. 15:10063–10069. 2018.PubMed/NCBI
39	Feng J, Wang X, Zhu W, Chen S and Feng C: MicroRNA-630 suppresses epithelial-to-mesenchymal transition by regulating FoxM1 in gastric cancer cells. Biochemistry. 82:707–714. 2017.PubMed/NCBI